UROV News and Press, Urovant Sciences Ltd. From 12/30/19

Urovant Sciences (Nasdaq: UROV) (“Urovant”) announced today that its majority shareholder, Roivant Sciences Ltd. (“Roivant”), and Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506) (“Sumitomo Dainippon Pharma”), a leading global Japanese pharmaceutical...

Urovant Sciences (Nasdaq: UROV), announced today that the first patient has been enrolled in a Phase 2a study evaluating the efficacy and safety of URO-902, a novel gene therapy product, in patients with overactive bladder (OAB) suffering with urge urinary incontinence (UUI). “We...

Urovant Sciences Ltd. (UROV) Q2 2019 Earnings Conference Call November 5, 2019 4:30 P.M. ET Company Participants Ryan Kubota - Executive Director of Investor Relations Keith Katkin - Chief Executive Officer Cornelia Haag-Molkenteller - Chief Medical Officer Christine Ocampo - ...

Image source: The Motley Fool. Urovant Sciences Ltd   (NASDAQ: UROV) Q2 2019 Earnings Call Nov 5, 2019 , 4:30 p.m. ET Operator Continue reading

Urovant Sciences (NASDAQ: UROV ): Q2 GAAP EPS of -$0.85 beats by $0.13 . More news on: Urovant Sciences Ltd., Earnings news and commentary, Healthcare stocks news, Read more ...

Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today reported financial results for the 2019 second fiscal quarter ended September 30, 2019. Recent Business Highlights ...

Sumitomo Dainippon Pharma has committed to provide an initial $200 million, low-interest, interest-only, five-year term loan facility, with no repayments due until the end of the term Sumitomo Dainippon Pharma expects to continue to fund Urovant Sciences’ operating needs through...

Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced it will report 2019 second fiscal quarter financial results after the close of U.S. financial markets on Tuesda...

Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced that it will be initiating part 2 of the COURAGE study, an international phase 3 trial to evaluate the safety a...

Biotech is in the doldrums. The SPDR S&P Biotech ETF  declined 18% in the past six months, and money continues to flow out of the sector. While several biotechs managed to IPO in September and October , it's not all roses. ADC Therapeutics pulled its plans to list citing market...